Joop van Gerven

7.9k total citations
168 papers, 6.0k citations indexed

About

Joop van Gerven is a scholar working on Cognitive Neuroscience, Cellular and Molecular Neuroscience and Pharmacology. According to data from OpenAlex, Joop van Gerven has authored 168 papers receiving a total of 6.0k indexed citations (citations by other indexed papers that have themselves been cited), including 61 papers in Cognitive Neuroscience, 46 papers in Cellular and Molecular Neuroscience and 45 papers in Pharmacology. Recurrent topics in Joop van Gerven's work include Neurotransmitter Receptor Influence on Behavior (28 papers), Neuroscience and Neuropharmacology Research (24 papers) and Sleep and Wakefulness Research (23 papers). Joop van Gerven is often cited by papers focused on Neurotransmitter Receptor Influence on Behavior (28 papers), Neuroscience and Neuropharmacology Research (24 papers) and Sleep and Wakefulness Research (23 papers). Joop van Gerven collaborates with scholars based in Netherlands, United States and United Kingdom. Joop van Gerven's co-authors include Adam F. Cohen, Rik C. Schoemaker, Serge A.R.B. Rombouts, Lineke Zuurman, Saco J. de Visser, Jasper Dingemanse, Marieke L. de Kam, Albert Dahan, Christian F. Beckmann and Glenn Dumont and has published in prestigious journals such as Nature Medicine, PLoS ONE and NeuroImage.

In The Last Decade

Joop van Gerven

166 papers receiving 5.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Joop van Gerven Netherlands	44	2.4k	1.7k	1.6k	1.2k	942	168	6.0k
Robert M. Swift United States	55	877 0.4×	1.1k 0.7×	3.7k 2.4×	983 0.8×	535 0.6×	195	10.1k
I. Hindmarch United Kingdom	41	2.0k 0.9×	1.6k 0.9×	693 0.4×	2.0k 1.7×	449 0.5×	186	6.4k
Deepak Cyril D’Souza United States	49	2.3k 1.0×	4.8k 2.7×	4.2k 2.6×	435 0.4×	330 0.4×	155	8.9k
Robert Malcolm United States	44	805 0.3×	1.1k 0.7×	1.9k 1.2×	594 0.5×	194 0.2×	140	6.0k
Lorenzo Leggio United States	56	763 0.3×	791 0.5×	2.3k 1.4×	542 0.5×	1.8k 1.9×	295	9.9k
Nakao Iwata Japan	52	1.5k 0.6×	1.5k 0.8×	3.0k 1.9×	941 0.8×	683 0.7×	482	11.4k
Kyle M. Kampman United States	47	953 0.4×	1.2k 0.7×	3.0k 1.9×	678 0.6×	118 0.1×	143	7.0k
Jonathon C. Arnold Australia	46	730 0.3×	3.4k 2.0×	2.1k 1.3×	189 0.2×	385 0.4×	135	5.2k
James Stone United Kingdom	46	2.1k 0.9×	1.9k 1.1×	2.8k 1.8×	415 0.4×	146 0.2×	164	8.6k
Alasdair M. Barr Canada	48	904 0.4×	765 0.4×	2.6k 1.6×	232 0.2×	272 0.3×	222	7.5k

Countries citing papers authored by Joop van Gerven

Since Specialization

Citations

This map shows the geographic impact of Joop van Gerven's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joop van Gerven with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joop van Gerven more than expected).

Fields of papers citing papers by Joop van Gerven

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joop van Gerven. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joop van Gerven. The network helps show where Joop van Gerven may publish in the future.

Co-authorship network of co-authors of Joop van Gerven

This figure shows the co-authorship network connecting the top 25 collaborators of Joop van Gerven. A scholar is included among the top collaborators of Joop van Gerven based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joop van Gerven. Joop van Gerven is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Schoones, Jan W., et al.. (2025). Clinical Pharmacokinetics of N,N-Dimethyltryptamine (DMT): A Systematic Review and Post-hoc Analysis. Clinical Pharmacokinetics. 64(2). 215–227. 4 indexed citations

Zuiker, Rob, Christopher Bryan, Nancy L. Stewart, et al.. (2025). Safety, Pharmacokinetics, and Pharmacodynamics of a 6‐h N,N‐Dimethyltryptamine (DMT) Infusion in Healthy Volunteers: A Randomized, Double‐Blind, Placebo‐Controlled Trial. Clinical and Translational Science. 18(5). e70234–e70234. 1 indexed citations

Zuiker, Rob, Jules A. A. C. Heuberger, Marieke de Kam, et al.. (2023). Administration of oxathridine, a first‐in‐class histamine‐3 receptor partial agonist in healthy male volunteers: Central nervous system depression and pseudo‐hallucinations. British Journal of Clinical Pharmacology. 90(1). 321–335.

Kam, Marieke L. de, et al.. (2023). Cognitive performance in healthy clinical trial participants and patients with the NeuroCart, a neurodegenerative disease measured with an automated neuropsychological and neurophysiological test battery. Journal of the Neurological Sciences. 449. 120658–120658. 1 indexed citations

Boer, Peter de, Peter van der Ark, Heike Beneš, et al.. (2023). Characterization of the central nervous system penetrant and selective purine P2X7 receptor antagonist JNJ-54175446 in patients with major depressive disorder. Translational Psychiatry. 13(1). 266–266. 36 indexed citations

Ferreira, Guilherme S., Désirée H. Veening-Griffioen, Wouter Boon, et al.. (2023). Translatability of preclinical to early clinical tolerable and pharmacologically active dose ranges for central nervous system active drugs. Translational Psychiatry. 13(1). 74–74. 3 indexed citations

Aart, Jasper van der, Gabriël E. Jacobs, Marieke de Kam, et al.. (2020). Characterisation of the pharmacodynamic effects of the P2X7 receptor antagonist JNJ-54175446 using an oral dexamphetamine challenge model in healthy males in a randomised, double-blind, placebo-controlled, multiple ascending dose trial. Journal of Psychopharmacology. 34(9). 1030–1042. 44 indexed citations

Rongen, Gerard A., Pierre Marquet, & Joop van Gerven. (2020). The scientific basis of rational prescribing. A guide to precision clinical pharmacology based on the WHO 6-step method. European Journal of Clinical Pharmacology. 77(5). 677–683. 8 indexed citations

Hart, Ellen P., et al.. (2019). A Computerized Test Battery to Study Pharmacodynamic Effects on the Central Nervous System of Cholinergic Drugs in Early Phase Drug Development. Journal of Visualized Experiments. 2 indexed citations

10.

Boer, Peter de, Wayne C. Drevets, Hany Rofael, et al.. (2018). A randomized Phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity. Journal of Psychopharmacology. 32(6). 668–677. 45 indexed citations

11.

Amerongen, Guido van, Jules A. A. C. Heuberger, Erica S. Klaassen, et al.. (2017). Effects on Spasticity and Neuropathic Pain of an Oral Formulation of Δ9-tetrahydrocannabinol in Patients With Progressive Multiple Sclerosis. Clinical Therapeutics. 40(9). 1467–1482. 59 indexed citations

12.

Simpraga, Sonja, et al.. (2017). EEG machine learning for accurate detection of cholinergic intervention and Alzheimer’s disease. Scientific Reports. 7(1). 5775–5775. 56 indexed citations

13.

Cohen, Adam F., Jacobus Burggraaf, Joop van Gerven, Matthijs Moerland, & Geert Jan Groeneveld. (2014). The Use of Biomarkers in Human Pharmacology (Phase I) Studies. The Annual Review of Pharmacology and Toxicology. 55(1). 55–74. 41 indexed citations

14.

Niesters, Marieke, Najmeh Khalili‐Mahani, Leon Aarts, et al.. (2012). Effect of Subanesthetic Ketamine on Intrinsic Functional Brain Connectivity. Anesthesiology. 117(4). 868–877. 104 indexed citations

15.

Hoch, Matthias, Justin L. Hay, Petra Hoever, et al.. (2012). Dual orexin receptor antagonism by almorexant does not potentiate impairing effects of alcohol in humans. European Neuropsychopharmacology. 23(2). 107–117. 18 indexed citations

16.

Zuiker, Rob, et al.. (2011). The Perception and Pharmacokinetics of a 20-mg Dose of Escitalopram Orodispersible Tablets in a Relative Bioavailability Study in Healthy Men. Clinical Therapeutics. 33(10). 1492–502. 15 indexed citations

17.

Gerven, Joop van, Glenn Dumont, S. Paltansing, et al.. (2008). A comparative study of two methods for attaining constant alcohol levels. British Journal of Clinical Pharmacology. 66(5). 674–681. 23 indexed citations

18.

French, Jacqueline A., Édouard Hirsch, J.P. Macher, et al.. (2007). Evaluation of carisbamate, a novel antiepileptic drug, in photosensitive patients: An exploratory, placebo-controlled study. Epilepsy Research. 74(2-3). 193–200. 28 indexed citations

19.

Haarst, Aernout D. van, Joop van Gerven, Rik C. Schoemaker, et al.. (1998). The influence of cisapride and clarithromycin on QT intervals in healthy volunteers. Clinical Pharmacology & Therapeutics. 64(5). 542–546. 125 indexed citations

20.

Tuk, Bert, Janine Oberyé, Monique S. M. Pieters, et al.. (1997). Pharmacodynamics of temazepam in primary insomnia: Assessment of the value of quantitative electroencephalography and saccadic eye movements in predicting improvement of sleep. Clinical Pharmacology & Therapeutics. 62(4). 444–452. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact